Business Wire

CA-BELKIN

4.1.2023 15:01:52 CET | Business Wire | Press release

Share
Belkin celebrates 40 years of industry leadership by introducing a more responsible way to build products

Belkin, a global consumer electronics leader, after two years of development, today introduces a new product material refresh for its top selling mobile power products. Several of Belkin’s most popular wireless chargers, power banks, wall chargers, and car chargers will receive updated product housing materials that consist of 73-75% post-consumer recycled plastics (PCR) and plastic-free packaging. The product transition will be rolled out beginning 2023 and will save an estimated 7,000 metric tons of carbon emissions1 and reduce CO2-eq emissions for these products by up to 67%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005370/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

The company celebrates 40 years as a market leader and innovator by honoring its deeply rooted commitment to sustainability. Belkin is already on its way to becoming 100% carbon neutral in scope 1 & 2 emissions by 2025. Its commitment to reviewing all areas of the business has included a focus on reducing single-use plastics in packaging which has seen up to a 90% reduction in plastic usage in some products. Today’s announcement addresses Belkin’s approach to reducing its scope 3 emissions.

Belkin made a deliberate and methodical decision to transition product materials to PCR. This takes plastic waste from consumers and repurposes it to create new products. It utilizes plastic that is destined for landfill, giving it new life, while taking meaningful steps to support the circular economy by reducing dependence on virgin plastics. The Life Cycle Assessment conducted by the company shows that utilizing PCR material has a significant reduction in environmental impact.

There are other plastic alternatives in the industry such as:

  • Recycled plastic (PIR), a method that reuses plastic materials collected at a factory during mass production
  • Bioplastics, which uses materials from renewable feedstocks such as plants and woodchips
  • Ocean plastics, which reuses plastic waste collected from the ocean

“When we think about the difference a company of our size and influence can make on the planet, moving away from using virgin plastics in our products is an obvious decision,” said Steve Malony, CEO, Belkin. “I am proud to work alongside the teams that made this shared vision a reality. Their dedication to doing the right thing inspires me and together, we will continue to work towards a more sustainable future.”

The following products will be the first to ship with the new PCR material throughout 2023:

From an aesthetic, quality and engineering perspective, there will be little difference between existing Belkin products and Belkin PCR products. Consumers will be able to decipher the new PCR products by clear callouts on the packaging and product pages online such as: “Made with Recycled Plastic Products” and “100% Plastic Free Packaging.”

Belkin’s engineering and product development teams are based in Los Angeles, Hong Kong, Shenzhen, Vietnam and Taiwan, and work tirelessly to develop innovation that changes the way people connect with their technology while reducing impact on the planet. Belkin takes quality seriously, and nothing enters the market until rigorous testing and approval processes take place. For this new PCR portfolio, Belkin additionally continues to explore new solutions and to conscientiously verify the science behind how Belkin can further reduce its impact on the planet while not compromising on quality. PCR material was sourced from reputable resin vendors and selected and tested by Belkin’s design assurance team.

To learn more about Belkin Sustainability, visit: https://www.belkin.com/company/sustainability/

Press kit can be found here.

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remain forever inspired by people and the planet we live on.

1 Based on forecasted calculations from May 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005370/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye